... of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Methods: A total of 90 patients with advanced HCC, Child-Pugh class A–B7 cirrhosis, and no prior systemic therapy were randomly assigned (1: 1...

...Cheol-Kyu Park; In-Jae Oh; Yoo-Duk Choi; Tae-Won Jang; Jeong-Eun Lee; Jeong-Seon Ryu; Shin-Yup Lee; Young-Chul Kim Objectives: We aimed to evaluate the prevalence and predictive role of c-MET expression and EGFR mutation in the efficacy of erlotinib in non-small-cell lung cancer (NSCLC). Methods...

... cancer (NSCLC) patients [ 2,3 ] and their association with remarkable response to EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib [ 2,3,4,5,6,7,8,9,10,11 ], have led to a paradigm shift in the management of advanced NSCLC. Adenocarcinoma Epidermal growth factor receptor...

...Renuka Iyer; Ravi Chhatrala; Tracey Shefter; Gary Yang; Usha Malhotra; Wei Tan; Charles LeVea; Melissa Robins; Nikhil Khushalani Purpose: Elderly patients with esophageal cancer who are not candidates for chemoradiation may benefit from targeted agents; hence erlotinib combined with radiotherapy...

...Chih-Hung Hsu; Yoon Koo Kang; Tsai-Shen Yang; Chia-Tung Shun; Yu-Yun Shao; Wu-Chou Su; Jennifer Sandoval-Tan; Tzeon-Jye Chiou; Kate Jin; Chiun Hsu; Ann-Lii Cheng Objectives: The bevacizumab/erlotinib combination was reported with high clinical activity for advanced hepatocellular carcinoma (HCC...

...J. Zugazagoitia; J. Puente; J.L. González-Larriba; A. Manzano; M. Sotelo; S. Hernández; J. Sanz; P. Pérez; E. Díaz-Rubio Background/Aim: Erlotinib and chemotherapy have shown similar efficacy for pretreated non-small cell lung cancer (NSCLC) patients, but none of the large studies have selected...

...A.O. Kaseb; E. Garrett-Mayer; J.S. Morris; L. Xiao; E. Lin; G. Onicescu; M.M. Hassan; H.M. Hassabo; M. Iwasaki; F.L. Deaton; J.L. Abbruzzese; M.B. Thomas Objective: A phase II study was performed to evaluate the efficacy and tolerability of bevacizumab and erlotinib in advanced hepatocellular...

...Seung Tae Kim; Jeeyun Lee; Jong-mu Sun; Yeon Hee Park; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn Purpose: To devise a prognostic model based on clinical parameters for non-small cell lung cancer (NSCLC) patients treated with erlotinib as a salvage therapy. Patients and Methods: Between July 2006...

... advantage from systemic chemotherapy. A further advantage was reported when docetaxel and pemetrexed were used as second-line treatment after failure of first-line platinum-based chemotherapy. Furthermore, the biologic therapies targeting the epidermal growth factor receptor – erlotinib and gefitinib – have...

...Sikander Ailawadhi; Lyudmyla Derby; Raj Natarajan; Gerald Fetterly; Mary Reid; Nithya Ramnath Background: Erlotinib is approved as treatment for metastatic non-small-cell lung cancer (NSCLC), following failure of initial therapy. Studies to define patients that derive maximal benefit from erlotinib...